Hyperuricemia, the heart, and the kidneys – to treat or not to treat?

References

• Prasad Sah OS, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon. 2015;7:e27233.
   PubMedGoogle Scholar
• Hyndman D, Liu S, Miner JN. Urate handling in the human body. Curr Rheumatol Rep. 2016;18(6):34.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–2228.
   PubMed Web of Science ®Google Scholar
• Ohno I. Relationship between hyperuricemia and chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1039–1044.
   PubMed Web of Science ®Google Scholar
• Eleftheriadis T, Golphinopoulos S, Pissas G, et al. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017;8(5):555–560.
   PubMed Web of Science ®Google Scholar
• Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.
   PubMed Web of Science ®Google Scholar
• Hosomi A, Nakanishi T, Fujita T, et al. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456.
   PubMed Web of Science ®Google Scholar
• Xu X, Li C, Zhou P, et al. Uric acid transporters hiding in the intestine. Pharm Biol. 2016;54(12):3151–3155.
   PubMed Web of Science ®Google Scholar
• Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017;36(12):2637–2644.
   PubMed Web of Science ®Google Scholar
• Mallat SG, Al Kattar S, Tanios BY, et al. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep. 2016;18(10):74.
   PubMed Web of Science ®Google Scholar
• Ferri C. The problem of cardio-renal diseases in patients with gout. Curr Med Res Opin. 2017;33(Suppl. 3):9–13.
   PubMedGoogle Scholar
• Li M, Li X, Liu Y, et al. Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta. 2018;486:156–161.
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134–F1141.
   PubMed Web of Science ®Google Scholar
• Fang P, Li X, Luo JJ, et al. A double-edged sword: uric acid and neurological disorders. Brain Disord Ther. 2013;2(2):109.
   PubMedGoogle Scholar
• Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: a need for caution. Semin Arthritis Rheum. 2017;46(4):457–464.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kaze AD, McMullan CJ, et al. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71(3):362–370.
   PubMed Web of Science ®Google Scholar
• Ramirez MEG, Bargman JM. Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy – a review. J Adv Res. 2017;8(5):551–554.
   PubMed Web of Science ®Google Scholar
• Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–191.
   PubMed Web of Science ®Google Scholar
• Chalès G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine. 2018;86:437–443.
   PubMed Web of Science ®Google Scholar
• Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421–426.
   PubMedGoogle Scholar
• Ali N, Perveen R, Rahman S, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: a study on Bangladeshi adults. PLoS One. 2018;13(11):e0206850.
   PubMed Web of Science ®Google Scholar
• Dong H, Xu Y, Zhang X, et al. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. Sci Rep. 2017;7(1):8822.
   PubMedGoogle Scholar
• Larsson SC, Burgess S, Michaëlsson K. Genetic association between adiposity and gout: a Mendelian randomization study. Rheumatology (Oxford). 2018;57(12):2145–2148.
   PubMed Web of Science ®Google Scholar
• Zheng C, Song H, Wang S, et al. Serum uric acid is independently associated with risk of obstructive sleep apnea–hypopnea syndrome in Chinese patients with type 2 diabetes. Dis Markers. 2019;2019:4578327.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lin G, Chen L, et al. Does continuous positive airway pressure therapy in patients with obstructive sleep apnea improves uric acid? A meta-analysis. Oxid Med Cell Longev. 2019;2019:4584936.
   PubMed Web of Science ®Google Scholar
• García-Arroyo FE, Gonzaga G, Muñoz-Jiménez I, et al. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018;13(8):e0202901.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang C, Zeng X, et al. Microecological treatment of hyperuricemia using Lactobacillus from pickles. BMC Microbiol. 2020;20(1):195.
   PubMed Web of Science ®Google Scholar
• Hu AM, Brown JN. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Clin Rheumatol. 2020.
   Google Scholar
• Šmelcerović A, Tomović K, Šmelcerović Ž, et al. Xanthine oxidase inhibitors beyond allopurinol and febuxostat: an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem. 2017;135:491–516.
   PubMed Web of Science ®Google Scholar
• Kwak CH, Sohn M, Han N, et al. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease. Int J Clin Pharmacol Ther. 2018;56(7):321–327.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with Gout. N Engl J Med. 2018;378(13):1200–1210.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167–3181.
   PubMed Web of Science ®Google Scholar
• Kuriyama S. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clin Exp Nephrol. 2020;24(Suppl. 1):1–5.
   PubMed Web of Science ®Google Scholar
• Nieradko-Iwanicka B. What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? Reumatologia. 2018;56(2):106–110.
   PubMedGoogle Scholar
• Azevedo VF, Kos IA, Vargas-Santos AB, et al. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59(1):37.
   PubMedGoogle Scholar
• Yu H, Liu X, Song Y, et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol. 2018;22(6):1324–1330.
   PubMed Web of Science ®Google Scholar
• Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018;33(9):1620–1627.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60.
   PubMed Web of Science ®Google Scholar
• Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs. 2018;27(5):437–444.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Brucato A, Cianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: a critical appraisal. Eur J Intern Med. 2020;74:8–17.
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Køber L, Jhund PS, et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20(3):514–522.
   PubMed Web of Science ®Google Scholar
• Viggiano D, Gigliotti G, Vallone G, et al. Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound. Kidney Blood Press Res. 2018;43(2):606–615.
   PubMed Web of Science ®Google Scholar
• Ueno S, Hamada T, Taniguchi S, et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study. Drug Res (Stuttg). 2016;66(12):628–632.
   PubMed Web of Science ®Google Scholar
• Rubio-Guerra AF, Garro-Almendaro AK, Elizalde-Barrera CI, et al. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis. 2017;11(2):57–62.
   PubMedGoogle Scholar
• Derosa G, Maffioli P, Reiner Ž, et al. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76(9):947–956.
   PubMed Web of Science ®Google Scholar
• Kose E, An T, Kikkawa A, et al. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull. 2014;37(2):226–231.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462.
   PubMed Web of Science ®Google Scholar
• Fralick M, Chen SK, Patorno E, et al. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186–194.
   PubMed Web of Science ®Google Scholar
• Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol. 2018;29(5):1–5.
   PubMed Web of Science ®Google Scholar
• Zhang YF, He F, Ding HH, et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technol Med Sci. 2014;34(4):476–481.
   PubMedGoogle Scholar
• Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69(6):1036–1044.
   PubMed Web of Science ®Google Scholar
• Abeles AM. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015;17(3):13.
   PubMed Web of Science ®Google Scholar
• Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 2014;107(4):235–241.
   PubMed Web of Science ®Google Scholar
• Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.
   PubMed Web of Science ®Google Scholar
• Butkovič M. Urate as a potential risk factor of cardiovascular and renal diseases. Acta Med Croatica. 2016;70:233–239.
   PubMedGoogle Scholar
• Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19(6):386–391.
   PubMed Web of Science ®Google Scholar
• Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget. 2017;8(46):80688–80699.
   PubMedGoogle Scholar
• Kiss LZ, Bagyura Z, Csobay-Novák C, et al. Serum uric acid is independently associated with coronary calcification in an asymptomatic population. J Cardiovasc Transl Res. 2018;12(3):204–210.
   PubMed Web of Science ®Google Scholar
• Pilemann-Lyberg S, Hansen TW, Tofte N, et al. Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes. Diabetes Care. 2019;42(6):1088–1094.
   PubMed Web of Science ®Google Scholar
• Borghi C, Palazzuoli A, Landolfo M, et al. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure. Heart Fail Rev. 2020;25(1):43–51.
   PubMed Web of Science ®Google Scholar
• Sarvepalli PS, Fatima M, Quadri AK, et al. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl. 2018;29(5):1050–1056.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Choi HK, Yeo AE, et al. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. Hypertension. 2019;74(1):95–101.
   PubMed Web of Science ®Google Scholar
• Xin W, Mi S, Lin Z. Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials. Cardiovasc Ther. 2016;34(6):441–449.
   PubMed Web of Science ®Google Scholar
• Alem MM. Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018;36(4):e12432.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Pirro M, Watts GF, et al. Effects of allopurinol on endothelial function: a systematic review and meta-analysis of randomized placebo-controlled trials. Drugs. 2018;78(1):99–109.
   PubMed Web of Science ®Google Scholar
• Tsuruta Y, Kikuchi K, Tsuruta Y, et al. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: a randomized controlled study. Hemodial Int. 2015;19(4):514–520.
   PubMed Web of Science ®Google Scholar
• Alshahawey M, Shahin SM, Elsaid TW, et al. Effect of febuxostat on the endothelial dysfunction in hemodialysis patients: a randomized, placebo-controlled, double-blinded study. Am J Nephrol. 2017;45(5):452–459.
   PubMed Web of Science ®Google Scholar
• Chewcharat A, Chen Y, Thongprayoon C, et al. Febuxostat as a renoprotective agent for treatment of hyperuricemia: a meta-analysis of randomized controlled trials. Intern Med J. 2020.
   Google Scholar
• Bredemeier M, Lopes LM, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18(1):24.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020;27(2):121–128.
   PubMed Web of Science ®Google Scholar
• Ferraro PM, Curhan GC. Serum uric acid and risk of kidney stones. Am J Kidney Dis. 2017;70(2):158–159.
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122–134.
   PubMed Web of Science ®Google Scholar
• Tsai CW, Lin SY, Kuo CC, et al. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017;12(1):e0170393.
   PubMed Web of Science ®Google Scholar
• Momoki K, Kataoka H, Moriyama T, et al. Hyperuricemia as a predictive marker for progression of nephrosclerosis: clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis. J Atheroscler Thromb. 2017;24(6):630–642.
   PubMed Web of Science ®Google Scholar
• Buzas R, Tautu OF, Dorobantu M, et al. Serum uric acid and arterial hypertension—data from Sephar III survey. PLoS One. 2018;13(7):e0199865.
   PubMed Web of Science ®Google Scholar
• Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6(10):2470–2477.
   PubMed Web of Science ®Google Scholar
• Kim CS, Jin DC, Yun YC, et al. Relationship between serum uric acid and mortality among hemodialysis patients: retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 2017;36(4):368–376.
   PubMed Web of Science ®Google Scholar
• Petreski T, Bevc S, Ekart R, et al. Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis. Clin Nephrol. 2017;88(S1):69–72.
   PubMedGoogle Scholar
• Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis. Int Urol Nephrol. 2019;51(6):1013–1018.
   PubMed Web of Science ®Google Scholar
• Vargas-Santos AB, Peloquin CE, Zhang Y, et al. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med. 2018;178(11):1526–1533.
   PubMed Web of Science ®Google Scholar
• Zeng XX, Tang Y, Hu K, et al. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article. Medicine (Baltimore). 2018;97(13):e0161.
   PubMed Web of Science ®Google Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang H, Ma R, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3–5. Clin Exp Nephrol. 2019;23(3):362–370.
   PubMed Web of Science ®Google Scholar
• Tsuruta Y, Mochizuki T, Moriyama T, et al. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol. 2014;33(11):1643–1648.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–950.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778–1786.
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019;51(3):467–473.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Ohishi K, Takeda A, et al. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol. 2018;22(6):1300–1308.
   PubMed Web of Science ®Google Scholar
• Mizukoshi T, Kato S, Ando M, et al. Renoprotective effects of topiroxostat for hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): a prospective, randomized, multicentre clinical trial. Nephrology (Carlton). 2018;23(11):1023–1030.
   PubMed Web of Science ®Google Scholar
• De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71(1):157–158.
   PubMed Web of Science ®Google Scholar
• Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495–503.
   PubMed Web of Science ®Google Scholar
• Das S, Goswami RP, Ghosh A, et al. Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: an ultrasonographic perspective. Mod Rheumatol. 2017;27(3):518–523.
   PubMed Web of Science ®Google Scholar
• Piko N, Ekart R, Bevc S, et al. Atherosclerosis, epigenetic modifications, and arterial stiffness. Acta Med Biotechn. 2017;10(2):10–17.
   Google Scholar